1 / 11

Name MHRA Date 2007

11 th GHTF CONFERENCE WASHINGTON DC OCTOBER 2007 SG5: CLINICAL EVALUATION STATUS REPORT SUSANNE LUDGATE. Name MHRA Date 2007. ROLE. to work towards convergence of clinical evidence requirements to yield common data for the purpose of acceptance by global regulators.

tpollock
Télécharger la présentation

Name MHRA Date 2007

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 11th GHTF CONFERENCEWASHINGTON DCOCTOBER 2007SG5: CLINICAL EVALUATIONSTATUS REPORTSUSANNE LUDGATE Name MHRA Date 2007

  2. ROLE to work towards convergence of clinical evidence requirements to yield common data for the purpose of acceptance by global regulators • harmonised definitions • harmonised guidance • MOU ISO TC 194

  3. MEMBERSHIP • Commission, COCIR, EDMA, EUCOMED • FDA, AdvaMed, NEMA • Health Canada, MEDEC • TGA, MIAA • MHLW, JFMDA

  4. DOCUMENT FINALISED • clinical investigation • clinical data • clinical evaluation • clinical evidence • process data generation, clinical evaluation clinical evidence: key definitions and concepts (N1R8)

  5. DOCUMENT FINALISED • when, why, process • general principles (scope, how performed, who performs) • sources of data (experience, literature, investigation) • appraisal • analysis • clinical evaluation report clinical evaluation (N2/R8)

  6. IMPLEMENTATION PLANS • Japan: intending to implement • EU: already implemented • Australia: progress in implementation • Canada: intentions incorporated in Regulations • USA: law and definitions compatible

  7. DOCUMENT IN PROGRESS IVD Subgroup (SG1) Chair: Nancy Shadeed “…..responsible for working on a harmonised format for pre-market submissions…..”

  8. DOCUMENT IN PROGRESS • when undertaken/ general principles • general principles need • general principles design • specific details design • ethical considerations clinical investigation

  9. DOCUMENT IN PROGRESS • what is it • when needed • type of study • plan, objectives post-market clinical follow-up studies

  10. OBSTACLES • impact local law and regulations • layers of review • time to feedback • lack mechanism to facilitate similar documents

  11. THE FUTURE….. following completion of stated documents….. No further plans!!

More Related